Report cover image

Huntington’s Disease: Opportunity Assessment and Forecast

Publisher GlobalData
Published Oct 08, 2025
Length 84 Pages
SKU # GBDT20610477

Description

Huntington’s Disease: Opportunity Assessment and Forecast

Summary

This report covers the 7MM and provides an Excel-based forecast model for the Huntington’s Disease market through 2034.

The current HD treatments are used to alleviate the symptoms associated with the disease, with all of the approved drugs indicated for the management of chorea associated with HD. VMAT2 inhibitors dominated the HD market in 2024, accounting for 99.8% of sales in the 7MM. The key focus in the pipeline is on developing DMTs for HD, and huntingtin-lowering strategies are key area of development. Companies are pursuing various mechanisms to achieve this, including gene therapies, antisense oligonucleotides (ASOs), and oral therapeutics. The HD market across the 7MM was valued at $0.3 billion in the 2024 baseline year and is projected to grow at a compound annual growth rate (CAGR) of 27.4%, reaching $3.8 billion by 2034. A key driver of growth will be the launch of seven late-stage pipeline products, including the first DMTs for HD.

Scope
  • Overview of Huntington’s Disease (HD), including epidemiology, symptoms, diagnosis, and disease management.
  • Annualized HD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2024 to 2034.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the HD market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for HD. The most promising candidates in late-stage development are profiled.
  • Analysis of the current and future market competition in the 7MM HD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the 7MM HD therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HD therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Please note:this is delivered as a Zip file.

Table of Contents

84 Pages
Abbreviations
Related Reports
Executive Summary
Disease Overview
Overview of HD
Pathophysiology of HD
Staging Systems of HD
Huntington’s Disease Integrated Staging System
HD SWOT Analysis
Epidemiology
Diagnosed Incident Cases of Manifest HD, Both Sexes, All Ages, 2024–34
Age-Specific Trends in Diagnosed Incident Cases of Manifest HD, Both Sexes, 2024
Sex-Specific Diagnosed Incident Cases of Manifest HD, All Ages, 2024
Diagnosed Prevalent Cases of All HD (Premanifest and Manifest Combined), Both Sexes, All Ages, 2024–34
Diagnosed Prevalent Cases of Premanifest HD, Both Sexes, All Ages, 2024–34
Diagnosed Prevalent Cases of Manifest HD, Both Sexes, All Ages, 2024–34
Age-Specific Trends in Diagnosed Prevalent Cases of Manifest HD, Both Sexes, 2024
Sex-Specific Diagnosed Prevalent Cases of Manifest HD, All Ages, 2024
Diagnosed Prevalent Cases of Manifest HD by Type, All Ages, Both Sexes, 2024
Diagnosed Prevalent Cases of Adult-Onset Manifest HD by Stage, All Ages, Both Sexes, 2024
Sources and Methodology for Diagnosed Incident Cases of Manifest HD
Sources and Methodology for Diagnosed Prevalent Cases of All HD
Sources and Methodology for Diagnosed Prevalent Cases of Premanifest HD
Sources and Methodology for Diagnosed Prevalent Cases of Manifest HD
Sources and Methodology for Manifest HD by Type
Sources and Methodology for Adult-Onset Manifest HD by Stage
Sources and Methodology for Diagnosed Incident Cases of Manifest HD
Sources and Methodology for Diagnosed Prevalent Cases of All HD
Sources and Methodology for Diagnosed Prevalent Cases of Premanifest HD
Sources and Methodology for Diagnosed Prevalent Cases of Manifest HD
Current Treatment Options
Treatment Paradigm
Current Treatment Options
Product Profile: Bausch Health’s Xenazine/Nitoman/Choreazine (tetrabenazine)
Product Profile: Teva’s Austedo/Austedo XR (deutetrabenzine/deutetrabenzine ER)
Product Profile: Neurocrine Biosciences’ Ingrezza/Ingrezza Sprinkle (valbenazine)
Product Profile: Sanofi’s Tiaprizal/Tiapridal/Sereprile/Gramalil (tiapride)
Patient Flow: HD in 2024 Across 7MM
Unmet Needs and Opportunities
Unmet Needs in HD
Disease-Modifying Therapies
Early Diagnosis and Consensus on Disease Staging
Treatment Options for Cognitive and Psychiatric Symptoms
R&D Strategies
Trends in Clinical Trial Design in HD
Trends in Deal-Making in HD
Pipeline Assessment
HD Pipeline Overview
Late-Stage Pipeline Agents for HD
Product Profile: SOM Biotech’s SOM-3355 (bevantolol hydrochloride)
Product Profile: Prilenia Therapeutics’ Huntexil (pridopidine)
Product Profile: Roche’s RG6042 (tominersen)
Product Profile: Wave Life Sciences’ WVE-003
Product Profile: uniQure’s AMT-130 (ifezuntirgene inilparvovec)
Product Profile: PTC Therapeutics/Novartis’s PTC518 (votoplam)
Product Profile: Skyhawk Therapeutics’ SKY-0515
HD: Clinical Trials (Phase II/III) Overview
Market Outlook
HD Market Forecast
Market Drivers and Barriers
Appendix
Primary Research: KOL Information
Primary Research: High Prescriber Survey Information
Bibliography
About the Authors
Contact Us

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us